Monoclonal Antibodies in Cancer Immunotherapy

Monoclonal antibodies are laboratory-produced immunoglobulins of a single, defined specificity that are used as anticancer agents to bind precise molecular targets on tumour cells or their signalling environment. They can block growth-receptor signalling, mark tumour cells for destruction by the immune system, or deliver attached payloads, and they form one of the principal classes of biological cancer therapy.

Definition

A therapeutic monoclonal antibody is an immunoglobulin produced from a single B-cell clone (or its engineered equivalent) so that all molecules share one antigen specificity, used in cancer to bind a defined tumour-associated antigen or ligand and thereby block signalling or recruit immune effector mechanisms.

Scope

This topic covers how monoclonal antibodies are generated and engineered, their effector mechanisms (signal blockade, antibody-dependent and complement-dependent cytotoxicity), the concept of antibody-drug conjugates, and representative examples directed at receptors such as HER2 and EGFR. Immune-checkpoint antibodies are treated in a dedicated sibling topic. This entry is reference-educational and gives no dosing or treatment advice.

Core questions

• How are monoclonal antibodies of defined specificity produced and humanised?
• Through what mechanisms — signal blockade, ADCC, CDC, payload delivery — do they exert antitumour effects?
• How does target expression on the tumour determine which antibody is appropriate?
• What distinguishes a naked antibody from an antibody-drug conjugate?

Key concepts

• Single (monoclonal) antigen specificity
• Hybridoma technology
• Chimeric, humanised, and fully human antibodies
• Antibody-dependent cellular cytotoxicity (ADCC)
• Complement-dependent cytotoxicity (CDC)
• Receptor signal blockade (HER2, EGFR)
• Antibody-drug conjugates
• Immunogenicity

Key theories

Antigen-directed targeting via hybridoma technology

Fusing an antibody-producing B cell with a myeloma cell yields an immortal hybridoma secreting antibody of a single predefined specificity, the technical basis that made therapeutic monoclonal antibodies possible.

Mechanisms

A therapeutic monoclonal antibody binds a defined antigen through its variable region and can act by several mechanisms. By occupying a growth-factor receptor or its ligand it blocks the signalling that drives tumour proliferation, as with anti-HER2 and anti-EGFR antibodies. Through its constant (Fc) region it can engage immune effector cells to mediate antibody-dependent cellular cytotoxicity and can activate the complement cascade to produce complement-dependent cytotoxicity. Antibodies can also serve as carriers, delivering a cytotoxic drug or radionuclide selectively to antigen-bearing cells as an antibody-drug conjugate. Early murine antibodies provoked immune responses in patients, which drove the engineering of chimeric, humanised, and fully human antibodies to reduce immunogenicity.

Clinical relevance

Monoclonal antibodies are integral to modern oncology and illustrate how a tumour's surface biology guides therapy selection — for example, testing for receptor overexpression before using a receptor-directed antibody. This entry describes the class mechanistically to support understanding of how antibody therapies are categorised and act; it is reference-educational and not a basis for individual diagnostic or treatment decisions.

Evidence & guidelines

Pivotal trials established antibody therapy in oncology: addition of trastuzumab to chemotherapy improved outcomes in HER2-overexpressing metastatic breast cancer, and cetuximab demonstrated activity in EGFR-expressing irinotecan-refractory metastatic colorectal cancer. Mechanistic reviews describe how receptor blockade and immune effector functions contribute to antibody efficacy.

History

The class was made possible by Köhler and Milstein's 1975 hybridoma technique, which produced antibodies of a single predefined specificity. Translation to oncology accelerated once antibodies could be engineered to reduce immunogenicity, leading to chimeric and humanised therapeutics. The validation of trastuzumab against HER2-overexpressing breast cancer around 2001 and of cetuximab against EGFR in colorectal cancer established receptor-directed antibodies as a standard therapeutic strategy.

Debates

How much of an antibody's antitumour effect comes from signal blockade versus immune effector functions?

For receptor-directed antibodies the relative contributions of direct signalling blockade, antibody-dependent cellular cytotoxicity, and complement activation are difficult to disentangle and may differ between agents and tumour contexts.

Key figures

• Georges Köhler
• César Milstein
• Dennis Slamon
• Clifford Hudis

Seminal works

• kohler-milstein-1975
• slamon-2001
• cunningham-2004

Frequently asked questions

What makes an antibody 'monoclonal'?

A monoclonal antibody derives from a single B-cell clone, so every molecule recognises the same single epitope with identical specificity, in contrast to the mixture of specificities in a polyclonal antibody preparation.

How can a monoclonal antibody kill a cancer cell?

It can block a growth-promoting receptor, flag the cell for destruction by immune effector cells (ADCC) or complement (CDC), or deliver an attached cytotoxic payload selectively to antigen-bearing cells.